Company Overview - The stock price of Ascentage Pharma has shown volatility despite positive developments in research and development, with the stock performance not meeting expectations [1] - The company's new generation BTK degrader APG-3288 received clinical approval from the National Medical Products Administration of China on February 6, 2026, and initiated a global multi-center Phase I clinical trial for relapsed/refractory hematologic malignancies on February 11, 2026 [1] - As of February 13, the closing price of the stock was HKD 47.50, with a daily increase of 2.41%, but a year-to-date decline of 9.09% [1] Industry Context - The innovative drug sector is currently facing valuation adjustment pressure, with the market showing impatience towards the long-term commercialization of unprofitable biotech companies, focusing more on short-term profitability [1] - The Hong Kong biotechnology sector declined by 0.95%, while the Hang Seng Index fell by 1.72%, indicating that the sector underperformed the broader market, further intensifying individual stock pressures [1] Financial Performance - The core product, Nairik, saw sales revenue increase by 93% year-on-year to CNY 217 million in the first half of 2025, with another product, Lishengtuo, approved for market launch in July 2025 [2] - However, the net loss expanded to CNY 591 million during the same period, primarily due to reduced intellectual property licensing income and increased R&D expenditures [2] - Market focus is on key catalysts, such as overseas indication approvals, which are concentrated post-2027, leading to a lack of patience for long-term narratives and a greater emphasis on short-term performance [2] Market Sentiment - On February 12, there was a net outflow of HKD 4.926 million from major funds in the Hong Kong stock market, and a net outflow of HKD 11.534 million from retail investors, indicating strong short-term risk-averse sentiment [2] - Although there was a net inflow of HKD 1.4948 million on February 13, major funds still experienced a net outflow of HKD 193,900, reflecting cautious institutional attitudes [2] - Technical indicators show that while the MACD histogram has turned positive, the KDJ is in the oversold zone, suggesting weak short-term momentum [2] Future Outlook - The R&D progress of Ascentage Pharma provides long-term value support, but it has not fully offset industry adjustments, risk aversion in funding, and market concerns regarding profitability in the short term [2] - The stock's volatility reflects the market's balancing act between technological innovation and short-term performance [2]
亚盛医药股价震荡：研发利好难抵行业调整与资金避险压力